Companies founded on innovation and strong science

The proprietary platform allows the company to generate libraries of bispecific antibody-drug conjugates, multivalent multispecifics, or any combination thereof.

From a vast, untapped space of potential components and target combinations, the platform can rapidly identify the most potent drug candidates through iterative screening and design—leveraging its 1-day design process. With this, the company can create and find drugs that won’t otherwise be identified—unlocking the next generation of multifunctional antibody therapeutics.

Calluna has a robust pipeline of selective antibodies targeting immunological diseases with enhanced efficacy, including several first-in-class clinical candidates.

Calluna Pharma was formed in 2023 following the merger of Arxx Therapeutics and Oxitope Pharma. The Company is based in Oslo, Norway, with Forbion, p53, Sarsia and Investinor as
lead investors.

Teitur develops novel therapeutics for treating or preventing neurodegenerative diseases. The company’s ambition and commitment is to create new treatments for patients suffering from neurodegenerative diseases to help them live a longer, better and happier life.

From the Sortilins family of receptors, Teitur has developed cyclic peptides with a unique potential for addressing key pathologies across several neurodegenerative disorders.

More than 200 million patients suffer from neurodegenerative disorders world-wide. Today, no treatments are available to prevent the relentless progression of neurodegeneration, affecting memory, movement, and quality of life for them and their loved ones.

Teitur is dedicated to developing novel compounds that can address this unmet medical need and provide true disease modifying opportunities to improve the lives of patients. P53 Invest participated in a series A round lead by Sunstone Life Science Ventures and Sound Bioventures, together with Industrifonden and Innovestor’s Life Science Fund

Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis.

The company leverages more than 30 years of research by its scientific co-founders uncovering the pathobiology of S100A4; a Damage Associated Molecular Pattern protein upregulated upon stress or injury allowing cells to sense and react to danger. In chronically diseased tissue, S100A4 is inappropriately activated which leads to persistent inflammation and non-resolving tissue fibrosis.

Arxx’s lead candidate AX-202 is a high-affinity monoclonal antibody neutralizing the bioactivity of S100A4. AX-202 confers targeted, upstream and disease-specific modulation of the self-sustaining feedback loop driving persistent fibrogenesis. In 2023, Arxx Therapeutics merged with Oxitope Pharma to form Calluna Pharma. P53 took part in the subsequent Series A round which was led by Forbion.

Atai Life Sciences is a clinical-stage biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients.

It addressed the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.

The company aims to transform the treatment and redefine how the world approaches, prevents, and heals mental health disorders.

specialist scientific advisory network, provide guidance on bringing transformative ideas into the clinic. The Centenara Labs subsidiary companies share lab space, equipment, and offices, with plug-and-play access to a state-of-the-art research infrastructure.

It addressed the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.

The company aims to transform the treatment and redefine how the world approaches, prevents, and heals mental health disorders.

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies for cancer, infectious diseases, and autoimmune conditions.

The company is developing cutting-edge, targeted DNA vaccines for clinical use, based on a deep understanding of immunological principles. By intelligent design, Nykode’s platform can be tailored to induce the desired immune response profile correlating with protection for each specific disease with any given antigen. Hence, the Nykode Therapeutics technology platform has the potential to address many diseases with a high unmet medical need.